| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00415-011-6143-5 |
| P8608 | Fatcat ID | release_5pmcn3z2iredtioyxza2cizgt4 |
| P698 | PubMed publication ID | 21713585 |
| P50 | author | Pierre Lozeron | Q51697645 |
| P2093 | author name string | D Adams | |
| P2860 | cites work | Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy | Q24236599 |
| Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada | Q33991742 | ||
| Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy | Q38373628 | ||
| Safety and Tolerability of Immune Globulin Intravenous in Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Q38500022 | ||
| Natalizumab treatment in a patient with chronic inflammatory demyelinating polyneuropathy | Q42972399 | ||
| A current view of the diagnosis, clinical variants, response to treatment and prognosis of chronic inflammatory demyelinating polyradiculoneuropathy. | Q43078170 | ||
| Chronic inflammatory demyelinating polyneuropathy responsive to mycophenolate mofetil therapy | Q43153662 | ||
| Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial | Q43172858 | ||
| European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Pe | Q55052893 | ||
| Long-term regular plasmapheresis as a maintenance treatment for chronic inflammatory demyelinating polyneuropathy | Q56771974 | ||
| Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial | Q80454073 | ||
| Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy | Q82397762 | ||
| European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve | Q82741977 | ||
| Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy | Q83002417 | ||
| Randomised controlled trial comparing two different intravenous immunoglobulins in chronic inflammatory demyelinating polyradiculoneuropathy | Q84500145 | ||
| A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy | Q84798728 | ||
| P433 | issue | 9 | |
| P304 | page(s) | 1737-1741 | |
| P577 | publication date | 2011-06-29 | |
| P1433 | published in | Journal of Neurology | Q6295649 |
| P1476 | title | Advances in the treatment of chronic inflammatory demyelinating neuropathies in 2010 | |
| P478 | volume | 258 |
| Q41019958 | Diagnostic utility of somatosensory evoked potentials in chronic polyradiculopathy without electrodiagnostic signs of peripheral demyelination. |
| Q44253504 | Do Tregitopes have the potential to impact the current treatment landscape of autoimmune diseases? |
| Q39531026 | Teaching tolerance: New approaches to enzyme replacement therapy for Pompe disease |
Search more.